What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
Aimmune Therapeutics (NASDAQ: AIMT) won approval from the U.S. Food and Drug Administration for its first drug -- and there are two more important firsts.
Aimmune's Palforzia is the first approved drug to treat peanut allergies, and the first approved treatment for any kind of food allergy, giving it a home run that the company, patients, and investors can all celebrate. Since Aimmune's pipeline is all about treating food allergies, this approval may be viewed as a positive sign showing the company's method can deliver.
Image source: Getty Images.
Source Fool.com
